A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Thursday, June 18, 2015
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg
June 18, 2015
- Novartis International AG / Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone(R) 20mg . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
- Glatopa is the first FDA-approved, substitutable generic version of Copaxone(R) 20mg, a treatment for relapsing forms of multiple sclerosis
- Sandoz has begun shipping to US customers following recent FDA approval
- Novartis and Sandoz are driving access to a full range of differentiated, high-quality MS therapeutic options, complemented by a full range of support services
Holzkirchen, Germany, June 18, 2015 - Sandoz, a Novartis company, today announced the US launch of GlatopaTM, the first generic version of Teva's Copaxone(R) (glatiramer acetate injection) 20 mg/ml one-time-daily multiple sclerosis therapy.
"Sandoz, together with Momenta, is proud to announce the US market launch of a fully substitutable generic version of this important therapy, following FDA approval" said Peter Goldschmidt, President of Sandoz US.
MS is a debilitating disease affecting about half a million individuals in the US alone; only half of those diagnosed are currently treated.
Glatopa, developed in collaboration with Momenta and produced entirely in the US, is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with MS.